• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Assessment of 12 Qualitative RT-PCR commercial kits for the detection of SARS-CoV-2

tetano

Editor, Senior Moderator
J Med Virol


. 2021 Feb 25.
doi: 10.1002/jmv.26900. Online ahead of print.
Assessment of 12 Qualitative RT-PCR commercial kits for the detection of SARS-CoV-2


Asmaa M Altamimi[SUP] 1 [/SUP], Dalia A Obeid[SUP] 1 [/SUP], Taghreed A Alaifan[SUP] 1 [/SUP], Moroje T Taha[SUP] 1 [/SUP], Marwa T Alhothali[SUP] 1 [/SUP], Fahad A Alzahrani[SUP] 1 [/SUP], Ahmad M Albarrag[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: The emergence of the novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) in the late months of 2019 had the officials to declare a public health emergency leading to a global response. Public measurements rely on an accurate diagnosis of individuals infected with the virus by using real-time reverse transcriptase polymerase chain reaction (RT-PCR). The aim of our study is to relate the fundamental clinical and analytical performance of SARS-COV-2 (RT-PCR) commercial kits.
Methods: A total of 94 clinical samples were selected. Generally, 400 ?l of each respiratory specimen was subjected to extraction using ExiPrep 96 Viral RNA Kit. All kits master mix preparation, cycling protocol, thermocycler and results interpretation were carried out according to the manufacturer's instructions of use and recommendations.
Results: The performance of the kits was comparable except for the LYRA kit as it was less sensitive (F=67, P <0.001). Overall, four kits scored a sensitivity of 100% including: BGI, IQ Real, Sansure, and RADI. For specificity, all the tested kits scored above 95%. The performance of these commercial kits by gene target showed no significant change in Ct values which indicates that kits disparities are mainly linked to the oligonucleotide of the gene target.
Conclusion: We believe that most of the commercially available RT-PCR kits included in this study can be used for routine diagnosis of SARS-COV-2 patients. We recommend including kits with multiple targets in order to monitor the virus changes over time. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; Coronavirus; In vitro diagnostics; RT-PCR; SARS-CoV-2; nCoV-2019.
 
Back
Top Bottom